Evidence map›Paper›PMID 38051475›Full record

ArticleDrug delivery and translational research2024

Clopidogrel-loaded vascular grafts prepared using digital light processing 3D printing.

Masoud Adhami, Camila J Picco, Usanee Detamornrat, Qonita K Anjani, Victoria A Cornelius, Pamela Robles-Martinez, Andriana Margariti, Ryan F Donnelly, Juan Domínguez-Robles, Eneko Larrañeta

Open access · hybridAbstract read
In one paragraph

Article in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Masoud AdhamiSchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK.
Camila J PiccoSchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK.
Usanee DetamornratSchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK.
Qonita K AnjaniSchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK.
Victoria A CorneliusWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, BT9 7BL, UK.
Pamela Robles-MartinezUCL School of Pharmacy, University College London, WC1N 1AX, London, UK.
Andriana MargaritiWellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, BT9 7BL, UK.
Ryan F DonnellySchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK.
Juan Domínguez-RoblesSchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK. jdominguez6@us.es.
Eneko LarrañetaSchool of Pharmacy, Queen's University Belfast, Belfast, BT9 7BL, Northern Ireland, UK. e.larraneta@qub.ac.uk.ORCID 0000-0003-3710-0438
Queen's University Belfast · GBUniversity College London · GB

Funding

Ministerio de Ciencia e Innovación RYC-2021-034357-I
6 · The paper itself

Abstract

The leading cause of death worldwide and a significant factor in decreased quality of life are the cardiovascular diseases. Endovascular operations like angioplasty, stent placement, or atherectomy are often used in vascular surgery to either dilate a narrowed blood artery or remove a blockage. As an alternative, a vascular transplant may be utilised to replace or bypass a dysfunctional or blocked blood vessel. Despite the advancements in endovascular surgery and its popularisation over the past few decades, vascular bypass grafting remains prevalent and is considered the best option for patients in need of long-term revascularisation treatments. Consequently, the demand for synthetic vascular grafts composed of biocompatible materials persists. To address this need, biodegradable clopidogrel (CLOP)-loaded vascular grafts have been fabricated using the digital light processing (DLP) 3D printing technique. A mixture of polylactic acid-polyurethane acrylate (PLA-PUA), low molecular weight polycaprolactone (L-PCL), and CLOP was used to achieve the required mechanical and biological properties for vascular grafts. The 3D printing technology provides precise detail in terms of shape and size, which lead to the fabrication of customised vascular grafts. The fabricated vascular grafts were fully characterised using different techniques, and finally, the drug release was evaluated. Results suggested that the performed 3D-printed small-diameter vascular grafts containing the highest CLOP cargo (20% w/w) were able to provide a sustained drug release for up to 27 days. Furthermore, all the CLOP-loaded 3D-printed materials resulted in a substantial reduction of the platelet deposition across their surface compared to the blank materials containing no drug. Haemolysis percentage for all the 3D-printed samples was lower than 5%. Moreover, 3D-printed materials were able to provide a supportive environment for cellular attachment, viability, and growth. A substantial increase in cell growth was detected between the blank and drug-loaded grafts.

Indexed as

Blood Vessel ProsthesisClopidogrelPlatelet Aggregation InhibitorsPolyestersPrinting, Three-DimensionalDrug LiberationHumansPolyurethanesClopidogrelPlatelet Aggregation InhibitorspolycaprolactonePolyesterspoly(lactide)Polyurethanes3D printingClopidogrelDigital light processingVascular grafts

Identifiers

PMID38051475
PMCPMC11052781
OpenAlexW4389335248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.